Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00993694 |
Recruitment Status
:
Completed
First Posted
: October 12, 2009
Last Update Posted
: April 17, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
RATIONALE: Gathering information about how often methemoglobinemia occurs in young patients receiving dapsone for hematologic cancer or aplastic anemia may help doctors learn more about the disease and plan the best treatment.
PURPOSE: This research study is looking at methemoglobinemia in young patients with hematologic cancer or aplastic anemia treated with dapsone.
Condition or disease | Intervention/treatment |
---|---|
Chronic Myeloproliferative Disorders Leukemia Lymphoma Lymphoproliferative Disorder Methemoglobinemia Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms Nonmalignant Neoplasm | Drug: chemotherapy Drug: dapsone Other: medical chart review Procedure: assessment of therapy complications |
OBJECTIVES:
- Define the incidence of methemoglobinemia in patients with hematologic malignancy or aplastic anemia who received dapsone prophylaxis through a retrospective chart review encompassing the last 15 years.
- Identify major risk factors for developing methemoglobinemia.
OUTLINE: Medical charts are reviewed. Of particular interest is demographic information, reasons for beginning dapsone prophylaxis, duration of dapsone prophylaxis, dapsone dosing, methemoglobin level, and treatment with methylene blue.
Study Type : | Observational |
Actual Enrollment : | 41 participants |
Official Title: | Dapsone Induced Methemoglobinemia in Pediatric Hematologic Malignancy and Aplastic Anemia |
Actual Study Start Date : | January 2009 |
Actual Primary Completion Date : | December 2009 |
Actual Study Completion Date : | December 2009 |

- Incidence of methemoglobinemia in patients with hematologic malignancy or aplastic anemia who received dapsone prophylaxis through a retrospective chart review encompassing the last 15 years
- Major risk factors for developing methemoglobinemia

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | up to 18 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
-
Diagnosis of hematologic malignancy or aplastic anemia
- Treated within the past 15 years with dapsone prophylaxis during treatment of primary disease
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00993694
United States, Tennessee | |
Vanderbilt-Ingram Cancer Center - Cool Springs | |
Nashville, Tennessee, United States, 37064 | |
Vanderbilt-Ingram Cancer Center | |
Nashville, Tennessee, United States, 37232-6838 |
Principal Investigator: | Adam J. Esbenshade, MD | Vanderbilt-Ingram Cancer Center |
Responsible Party: | Adam Esbenshade, Assistant Professor of Pediatrics, Vanderbilt University |
ClinicalTrials.gov Identifier: | NCT00993694 History of Changes |
Obsolete Identifiers: | NCT00960050 |
Other Study ID Numbers: |
CDR0000652603 P30CA068485 ( U.S. NIH Grant/Contract ) VU-VICC-PED-0916 IRB# 090009 |
First Posted: | October 12, 2009 Key Record Dates |
Last Update Posted: | April 17, 2017 |
Last Verified: | April 2017 |
Keywords provided by Adam Esbenshade, Vanderbilt University:
methemoglobinemia aplastic anemia accelerated phase chronic myelogenous leukemia acute undifferentiated leukemia atypical chronic myeloid leukemia, BCR-ABL negative blastic phase chronic myelogenous leukemia childhood acute lymphoblastic leukemia in remission childhood acute myeloid leukemia in remission childhood chronic myelogenous leukemia chronic myelomonocytic leukemia chronic phase chronic myelogenous leukemia juvenile myelomonocytic leukemia mast cell leukemia meningeal chronic myelogenous leukemia progressive hairy cell leukemia, initial treatment |
prolymphocytic leukemia recurrent childhood acute lymphoblastic leukemia recurrent childhood acute myeloid leukemia refractory chronic lymphocytic leukemia refractory hairy cell leukemia relapsing chronic myelogenous leukemia secondary acute myeloid leukemia stage 0 chronic lymphocytic leukemia stage I chronic lymphocytic leukemia stage II chronic lymphocytic leukemia stage III chronic lymphocytic leukemia stage IV chronic lymphocytic leukemia T-cell large granular lymphocyte leukemia AIDS-related diffuse large cell lymphoma AIDS-related diffuse mixed cell lymphoma |
Additional relevant MeSH terms:
Lymphoma Disease Syndrome Leukemia Neoplasms Multiple Myeloma Neoplasms, Plasma Cell Anemia Myelodysplastic Syndromes Preleukemia Anemia, Aplastic Myeloproliferative Disorders Plasmacytoma Lymphoproliferative Disorders Myelodysplastic-Myeloproliferative Diseases |
Methemoglobinemia Neoplasms by Histologic Type Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Pathologic Processes Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Bone Marrow Diseases Precancerous Conditions |